Skip to content

Botox treatment of abdominal wall hernia

Botulinum Toxin Type A for Preoperative Treatment of Abdominal Wall Hernia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041230054
Enrollment
30
Registered
2023-06-30
Start date
2023-06-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abdominal wall hernia

Interventions

Four weeks before surgery, 200 U (50 U x 4 vials) of Botox Vista Injection diluted with 100 ml of fresh food or 100 U (50 U x 2 vials) of Botox Vista Injection diluted with 50 ml of fresh food is admi

Sponsors

Saito Takuya
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) For this study, patients with abdominal wall hernias with a hernia portal of 5 cm or more. 2) Patients with indications for abdominal wall hernia repair based on the preoperative evaluation. 3) Patients who are willing to comply with the research protocol. 4) Patients have signed a consent document approved by the Clinical Research Review Committee regarding participation in the study.

Exclusion criteria

Exclusion criteria: 1) Patients with active cancer. However, active cancer does not include intraepithelial carcinoma or lesions equivalent to intramucosal carcinoma that is considered curable by local treatment. 2) Patients with systemic muscle disease (myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, etc.). 3) Women who may be pregnant or are lactating. 4) Patients who are allergic to Botox. 5) Patients with severe psychosis or psychiatric symptoms that make it difficult for them to participate in the study. 6) Patients who are deemed ineligible for surgery. 7) Patients with a serious medical condition that would make it inappropriate for the investigator to participate in the study. 8) Patients with a history of abdominal surgery that is inoperable.

Design outcomes

Primary

MeasureTime frame
Recurrence rate at 1 year

Secondary

MeasureTime frame
Operating time, postoperative hospital stay, NRS (Numerical rating scale), SSI (Surgical site infection), seroma, mesh size, hernia portal measurement

Contacts

Public ContactSho Ueda

Aichi Medical University

ueda.shou.106@mail.aichi-med-u.ac.jp+81-561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026